Ulta Lab Tests

Quest AD-Detect Phosphorylated tau217 (p-tau217), Plasma

There are no preparation instructions.

The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.

QUEST AD DETECT PTAU217,

*Important Information on Lab Test Processing Times: Ulta Lab Tests is committed to informing you about the processing times for your lab tests processed through a national lab. Please note that the estimated processing time for each test, indicated in business days, is based on data from the past 30 days across the 13 laboratories for each test. These estimates are intended to serve as a guide and are not guarantees. Factors such as laboratory workload, weather conditions, holidays, and the need for additional testing or maintenance can influence actual processing times. We aim to offer estimates to help you plan accordingly. Please understand that these times may vary, and processing times are not guaranteed. Thank you for choosing Ulta Lab Tests for your laboratory needs.

The Quest AD-Detect Phosphorylated tau217 (p-tau217), Plasma test contains 1 test with 1 biomarker .

The Quest AD-Detect® Phosphorylated tau217 (p-tau217), Plasma test is a cutting-edge diagnostic tool designed to aid in the detection of Alzheimer's disease. This blood-based biomarker test focuses on measuring phosphorylated tau217, a key protein linked to the pathological processes of Alzheimer’s. With advancements in medical technology, this test provides a less invasive, reliable, and efficient alternative to cerebrospinal fluid (CSF) sampling or imaging tests.

What Does the Test Measure?
This test measures the levels of phosphorylated tau217 (p-tau217) in the plasma. Tau proteins are essential for stabilizing microtubules in nerve cells. However, in Alzheimer’s disease, abnormal tau proteins, such as p-tau217, accumulate and contribute to the formation of neurofibrillary tangles, one of the hallmarks of the disease. Elevated levels of p-tau217 in the plasma may indicate the presence of Alzheimer’s-related brain changes.

Who Should Consider This Test?

  • Individuals experiencing symptoms of cognitive decline, such as memory loss, confusion, or difficulty concentrating.
  • People with a family history of Alzheimer’s or other neurodegenerative diseases.
  • Those seeking an early evaluation to better understand their cognitive health.

Symptoms of Concern

  • Frequent forgetfulness, particularly of recent events.
  • Trouble with problem-solving or planning.
  • Difficulty completing familiar tasks.
  • Personality or mood changes.
  • Challenges in understanding visual or spatial relationships.

Benefits of the Test

  • Early Detection: Enables earlier identification of Alzheimer’s-related changes, potentially before significant cognitive decline.
  • Non-Invasive: A simple blood draw avoids the discomfort and risks associated with lumbar punctures or imaging procedures.
  • Actionable Results: Helps guide healthcare providers in determining next steps for diagnosis, treatment, or monitoring of cognitive health.
  • High Specificity: Focuses on a biomarker highly associated with Alzheimer’s disease, increasing diagnostic confidence.

What Happens Next?
Results from the AD-Detect® Phosphorylated tau217 test should be discussed with your healthcare provider. If elevated levels are found, further diagnostic evaluation, such as neuroimaging or comprehensive memory assessments, may be recommended. Early diagnosis allows individuals and their families to plan for the future, consider treatment options, and adopt strategies to support brain health.


The Quest AD-Detect® Phosphorylated tau217 (p-tau217), Plasma test represents a significant step forward in Alzheimer’s detection and management. By offering an accessible and reliable method for identifying Alzheimer’s-related biomarkers, this test empowers individuals and healthcare providers to take proactive steps toward preserving cognitive health.

Customer Reviews